News
09-28-2010, 09:42 PM
A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.
More... (http://www.news-medical.net/news/20100929/NCI-awards-AG-2412M-Phase-II-SBIR-grant-for-development-of-breast-cancer-drug-candidate.aspx)
More... (http://www.news-medical.net/news/20100929/NCI-awards-AG-2412M-Phase-II-SBIR-grant-for-development-of-breast-cancer-drug-candidate.aspx)